TITLE

TEVA REPORTS ON NEUROPROTECTION PROPERTIES OF COPAXONE

PUB. DATE
January 2003
SOURCE
Worldwide Biotech;Jan2003, Vol. 15 Issue 1, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Deals with the research made by Teva Pharmaceutical Industries Ltd. about the neuroprotective properties Copaxone for multiple sclerosis.
ACCESSION #
8775096

 

Related Articles

  • MS drug help.  // Drug Topics;2/6/95, Vol. 139 Issue 3, p20 

    Reports that the Pharmaceutical Marketing Alliance of Ronkonkoma, N.Y. will offer insurance guidance and information to multiple sclerosis patients receiving copolymer-1. Development of co-polymer 1 by Teva Pharmaceuticals; Contact number of Teva for more information.

  • Teva and Active Biotech amend marketing and distribution agreement.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p5 

    No abstract available.

  • Disappointing results from CORAL trial.  // Inside MS;Winter2002, Vol. 20 Issue 1, p37 

    Reports on the result of a multi-center clinical trial of oral Copaxone announced by Teva Pharmaceutical Industries Ltd. of Petah Tikva, Israel. Comparative effect of Copaxone and inactive placebo; Number of multiple sclerosis patients who participated in the trial; Recommendation of an...

  • Promoting `flawed' MS study backfires on drug company.  // Medical Marketing & Media;Nov99, Vol. 34 Issue 11, p12 

    Reports on mass media criticisms against United States-based Teva Pharmaceuticals for financing the promotion of a clinical study comparing multiple sclerosis. Teva's press releases for the study; Attack against the protocol for the study; Release of the study data in a poster session at the...

  • Options for multiple sclerosis therapy. Cotton, Paul // JAMA: Journal of the American Medical Association;11/9/94, Vol. 272 Issue 18, p1393 

    Introduces two drugs for the treatment of multiple sclerosis. Interferon beta-1a from Biogen Inc.; Copolymer 1 from Teva Pharmaceutical Industries; Criteria for approval by the Food and Drug Administration.

  • Copaxone, using different approach, also seeks FDA approval.  // Inside MS;Fall95, Vol. 13 Issue 3, p9 

    Reports that TEVA Pharmaceuticals Industries Ltd. is seeking approval from the Food and Drug Authority (FDA) for Copaxone for relapsing-remitting multiple sclerosis (MS). Reduction of rate of relapse.

  • New Study Demonstrated Significant Reduction in Annualized Relapse Rate and Halting of Disability Progression in MS Patients Switching To Copaxone(r).  // Biomedical Market Newsletter;5/14/2011, p102 

    The article focuses on the data announced by Teva Pharmaceutical Industries Ltd. related to two clinical studies, including QualiCop and Coptimize. It states that the Coptimize study was conducted in 19 countries on the impact of glatiramer acetate injection Copaxone on annualized relapse rate...

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;January 2004, Vol. 3 Issue 1, p6 

    Reports on pharmaceutical developments about multiple sclerosis. Study about the neuroprotective mechanism of Copaxone from Teva Pharmaceutical Industries Ltd.; Schering AG's clinical trial for Betaferon.

  • Teva/Active Biotech: laquinimod clinical program moves on.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p5 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics